HIF-PHI Mechanism of Action and HIF-PHI Clinical Trials

Advancing Equitable Care in Anemia of CKD: Minimizing Disease Burden and Health Disparities with Novel Agents and Shared Decision-Making


Jay B. Wish, MD

Professor of Clinical Medicine

Indiana University School of Medicine

Chief Medical Officer for Outpatient Dialysis

Indiana University Health

Indianapolis, Indiana

Program Overview

Anemia in CKD is a common complication that has been reported in approximately 6 million people with CKD in the United States. Recent advancements in the understanding of the pathophysiology of CKD-associated anemia has led to the discovery of a new class of drugs, yet nephrologists may lack awareness of these therapeutic developments. Additionally, certain healthcare disparities may limit comprehensive management across the broader population of patients with anemia and CKD, consequently increasing the global burden of this complication. To ensure appropriate care and outcomes for patients, nephrologists require up-to-date education on the pathophysiology of anemia and CKD, burden of disease, current and emerging treatment options, and barriers to care.

Target Audience

The educational design of this activity addresses the needs of nephrologists and/or nephrology allied healthcare providers.

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Summarize the mechanism of action and clinical trial efficacy and safety data of HIF-PH inhibitors.


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must
  • Read the learning objectives and faculty disclosures Complete the pretest
  • View the enduring material
  • Complete the posttest with a score of 70% or higher

A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

System Requirements

1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Term Offering

This activity was released on 2/26/2024 and is valid for one year. Requests for credit must be made no later than 2/26/2025.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com


Disclosures of Relevant Financial Relationships

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jay B. Wish, MDConsulting Fee (e.g., Advisory Board): GlaxoSmithKline, Fibrogen, AstraZeneca, Akebia, Otsuka, , Rockwell Medical, CSL Behring, Disc Medicine
Honoraria: GlaxoSmithKline, Fibrogen, AstraZeneca, Akebia, Otsuka, Rockwell Medical, CSL Behring, Disc Medicine
Speakers' Bureau: GlaxoSmithKline, Akebia, AstraZeneca

Milda Saunders, MD, MPH has no relevant financial relationships to disclose.

Edgar Lerma, MD
Honoraria: Travere, VIfor
Speakers' Bureaus: AstraZeneca, Callidita, GlaxoSmithKline, Otsuka, Travere
The following planners and managers involved in the development of this activity have no relevant financial relationships with ineligible companies to disclose.

The planners and managers at Global Education Group have no relevant financial relationships to disclose.

Iridium staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This activity is jointly provided by Global Education Group and Iridium Continuing Education.

This educational activity is supported by an independent educational grant from GlaxoSmithKline.

Credit Amount: 0.25
Credit Type: AMA
Release: 2/26/2024
Expiration: 2/26/2025